Open AccessEvaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris
Author(s) -
Dylan Haynes,
Jennifer L. Strunck,
Christina Topham,
Alex G. OrtegaLoayza,
Gail Kent,
Pamela B. Cassidy,
RongHua Hu,
Keith Choate,
Zhiping Wang,
Yuangang Liu,
Teri M. Greiling
Publication year - 2020
Publication title -
jama dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.128
H-Index - 166
eISSN - 2168-6084
pISSN - 2168-6068
DOI - 10.1001/jamadermatol.2020.0932
Subject(s) - medicine , pityriasis rubra pilaris , ixekizumab , psoriasis , dermatology life quality index , body surface area , psoriasis area and severity index , dermatology , secukinumab , psoriatic arthritis
Pityriasis rubra pilaris is a rare and disabling cutaneous disease that is frequently recalcitrant to conventional therapies and appears to involve interleukin (IL)-17 overexpression.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom